The Use of Inhaled Glucocorticosteroids (ICS) during the COVID-19 Pandemic

Abstract

The article analyzes 46 publications on the use of ICS for COVID-19. Both research results and their discussion by specialists are presented. The expediency of continuing basic therapy, including ICS, has been demonstrated in the event of COVID-19 in patients with bronchial asthma and chronic obstructive pulmonary disease. The risk of local immunosuppressive action of ICS has been compared with the ability to suppress inflammation in the initial period of COVID-19. Analysis of the publications suggests that it is safe to prescribe ICS to patients with COVID-19 as well as it is advisable to use them in the initial stages of this disease.